结合抗皮肤生长因子受体 (EGFR) 治疗与转移性结肠直肠癌 (mCRC) 的免疫治疗
Feng Xiong1, Yu-Wen Zhou1, Ya-Ting Hao2
1Department of Colorectal Cancer Center, West China Hospital of Sichuan University, Chengdu, China.
Expert review of gastroenterology & hepatology
|September 14, 2023
概括
将抗EGFR疗法与免疫疗法结合在一起,对治疗转移性结肠直肠癌 (mCRC) 有希望. 这种方法可以克服当前治疗方法的局限性,并改善耐火性mCRC患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 胃肠道瘤学 胃肠道瘤学
背景情况:
- 针对表皮生长因子受体 (EGFR) 的单克隆抗体,如 cetuximab 和 panitumumab,是转移性结直肠癌 (mCRC) 的标准向疗法.
- 目前的抗EGFR疗法存在局限性,无法充分利用其免疫调节潜力.
- 由于现有治疗方法的有效性有限,正在探索针对mCRC的免疫疗法,但单一疗法产生了不满意的结果.
研究的目的:
- 审查抗EGFR疗法的免疫调节作用,单独或与免疫疗法结合.
- 探索耐火性mCRC的新型组合治疗策略.
主要方法:
- 在PubMed和Medline数据库的文献中搜索有关mCRC组合治疗的相关研究.
- 综合关于抗EGFR药物和免疫治疗的免疫调节作用的现有知识.
主要成果:
- 抗EGFR疗法可以产生免疫调节作用.
- 将抗EGFR疗法与免疫疗法结合起来,表明了互补的机制和临床活性.
- 这种组合策略可能会增强mCRC的治疗效果.
结论:
- 虽然目前的治疗改善了生存率,但耐火性mCRC仍然是一个挑战.
- 结合抗EGFR疗法和免疫疗法是改善治疗疗效的有希望的策略.
- 这种组合方法有可能克服阻力并改善mCRC的结果.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy
554
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
554
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


